Skip to main contentLast updated: 17-Nov-2026
Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Stomach Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
Most advanced GISTs slowly learn to beat imatinib. When that happens, other tablets come next in a set order: sunitinib, then regorafenib, then ripretinib.
First check whether one spot is growing or many. One growing spot can often be removed or burned while the same tablet carries on.
Never stop the tablet on your own. A GIST can regrow fast when the drug is paused, so every change should be planned.
For the whole story of GIST, from the first test to imatinib and surgery, read our GIST treatment in Ahmedabad page. This post covers what happens when imatinib stops working.
It means the scan shows the tumour growing even though you take the tablet every day. It is called resistance, and it comes in two kinds.
Before anyone calls it failure, the scans are read with care. A responding tumour can look bigger on a scan when it is filling with fluid or bleeding inside, while it is actually dying. Doctors compare the density of the tumour as well as its size. Sometimes a second look or a different scan settles it. How the original gene result decides the first tablet is explained in our post on what your GIST gene report means.
This single question changes the plan. One spot growing while the rest stays quiet is a local problem. Many spots growing together is a drug problem.
This is where a surgeon sits with the medical oncologist. Dr Shah looks at whether the spot is safe to remove, what it would cost you in function, and whether it is the right moment. The role of surgery alongside tablets is also covered in our post on how surgery and imatinib are put in order.
Sometimes. If you have been on the usual dose and the tumour carries the most common gene change, a higher dose can win some more time before you switch.
The order is fixed by the trials that proved each drug. After imatinib comes sunitinib, then regorafenib, then ripretinib. A few people need a different drug from the start.
| Step | Drug | Why it is used here |
|---|---|---|
| Second | Sunitinib | Proved to slow growth after imatinib. Works well against some of the gene changes that cause resistance. |
| Third | Regorafenib | Slowed growth when imatinib and sunitinib had both failed. Covers some changes that sunitinib misses. |
| Fourth | Ripretinib | Slowed growth after three earlier drugs. Works across many gene changes and is gentler on the body. |
| Special case | Avapritinib | Meant for one rare gene change, PDGFRA D842V, which imatinib cannot touch. |
| Late options | Trial drugs, imatinib again, local treatment for comfort | Used when the standard steps are used up or out of reach. |
Ripretinib was also tested as a second step against sunitinib and did not beat it, so sunitinib stays second. Avapritinib was tested against regorafenib in people without the D842V change and did not win either, so it is not used outside that change. The studies are set out in plain words in our post on the key GIST studies and what is new.
Sunitinib is the usual second tablet. It works, but it brings tiredness, sore hands and feet, high blood pressure and a slow thyroid, all of which can be watched for and treated.
Regorafenib is hard on the hands and feet, and the skin care starts before the first tablet. Ripretinib is easier to take but costs far more.
A small group of GISTs carry this change. Imatinib does not work on them from the start, and avapritinib is the drug made for them.
When the tumour grows on treatment, a repeat test shows what has changed. It helps choose the next drug and the next trial, and is worth doing where it is available.
Because a GIST can regrow quickly when the drug is paused. A trial that stopped imatinib in people with a stable tumour saw fast progress in most of them.
Imatinib and sunitinib are made by Indian companies as generics and are within reach of many families. Ripretinib and avapritinib are costly and hard to get.
The tumour has found a way around the drug, usually through a new gene change. The scan is read with care first, because a tumour that is responding can sometimes look bigger.
Sunitinib is the usual second tablet. Regorafenib follows it, then ripretinib. A rare gene change called PDGFRA D842V is treated with avapritinib instead.
Often yes. A single growing spot can be removed, burned with a needle or treated with focused radiation, while the same tablet continues. This keeps later drugs in reserve.
It can help some people who grew on the usual dose and carry the common gene change. The gain is usually short, and it brings more side effects.
No. A GIST can regrow quickly when the drug is paused. Any break should be planned with your oncologist, including breaks for an operation.
Imatinib, sunitinib and regorafenib are available as generics. Ripretinib and avapritinib are costly and reached mostly through access programmes or trials.
It helps. A fresh sample from the growing spot shows what has changed. A blood test of tumour genes can do the same. Either one helps pick the next drug or trial.
For the full picture of GIST and its treatment, start at the GIST treatment in Ahmedabad page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
You have taken imatinib for a GIST, and now a scan says the tumour is growing again. That is a hard thing to hear, but it is not the end of the road. Several other tablets exist, and a single growing spot can often be dealt with on its own. This post explains what resistance means, what is tried in what order, and where surgery still helps. Dr Harsh Shah, a stomach cancer surgeon in Ahmedabad, reviews your scans and reports and plans the local treatment with your medical oncologist. Bring everything you have. You can call us or book by message. Call For Appointment Book on WhatsApp Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.
Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.